prikaz prve stranice dokumenta Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment
  Download
PDF 1.59 MB
master's thesis
Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment
2021. urn:nbn:hr:171:067672
Lange, Matthias
University of Split
School of Medicine
Medical chemistry and biochemistry

Cite this document

Lange, M. (2021). Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:067672

Lange, Matthias. "Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment." Master's thesis, University of Split, School of Medicine, 2021. https://urn.nsk.hr/urn:nbn:hr:171:067672

Lange, Matthias. "Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment." Master's thesis, University of Split, School of Medicine, 2021. https://urn.nsk.hr/urn:nbn:hr:171:067672

Lange, M. (2021). 'Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment', Master's thesis, University of Split, School of Medicine, accessed 22 November 2023, https://urn.nsk.hr/urn:nbn:hr:171:067672

Lange M. Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment [Master's thesis]. Split: University of Split, School of Medicine; 2021 [cited 2023 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:171:067672

M. Lange, "Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment", Master's thesis, University of Split, School of Medicine, Split, 2021. Available at: https://urn.nsk.hr/urn:nbn:hr:171:067672

Please login to the repository to save this object to your list.
Metadata
TitleDistinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment
Title (croatian)Izrazita ekspresija GD3 u subpopulacijama raka dojke nakon liječenja novim derivatom tieno[2,3-b]piridina
AuthorMatthias Lange
MentorVedrana Čikeš Čulić (mentor)
Committee memberAnita Markotić (predsjednik povjerenstva)
Committee memberNikolina Režić Mužinić (član povjerenstva)
Committee memberRenata Pecotić (član povjerenstva)
GranterUniversity of Split
School of Medicine
(Medical chemistry and biochemistry)
Split
Defense date and country2021-07-16, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Medical Biochemistry
Abstract
Objectives: The goal of this study was to determine GD3 expression after treatment with the novel thieno[2,3-b]pyridine derivative, by focusing on CD44+/CD24- CSCs, CD44- epithelial cells, as well as CD44+/ CD24+ hybrid cells. Methods: The MDA-MB-231 cell line was treated with 3-amino-N-(3-chloro-2- methylphenyl)-5-oxo-5,6,7,8-tetrahydrothieno[2,3-b]quinoline-2-carboxamide (compound 1). Cells were plated onto six-well plates and treated with 2 M compound 1 for 48 h. Following this, cells were stained with anti-GD3, anti-CD44 and anti-CD24 antibodies, and then analyzed via flow cytometry. The acquisition of data of triple-stained samples was done by a BD Accuri C6 cytometer (BD Biosciences) and analyzed with the FlowLogic Software. Results: Treatment of MDA-MB-231 cells with compound 1 has led to a reduction of the expression of GD3 in CD44+/CD24- CSCs, as well as CD44- epithelial cells. GD3 expression in CD44+/CD24+ hybrid cells was not significantly reduced. Conclusion: Due to its ability to reduce GD3 expression in different breast cancer subpopulations, compound 1 has a potential to be used in the treatment of triple-negative breast cancer.
Abstract (croatian)
Ciljevi: Cilj ove studije bio je utvrditi ekspresiju GD3 nakon tretmana novim derivatom tieno[2,3-b]piridina, posebice na CD44+/CD24- matičnim stanicama raka (CSC), CD44- epitelnim stanicama, kao i CD44+/CD24+ hibridnim stanicama. Metode: Stanična linija MDA-MB-231 tretirana je s 3-amino-N-(3-kloro-2-metilfenil)-5- okso-5,6,7,8-tetrahidrotienom[2,3-b]kinolin-2-karboksamid (spoj 1). Stanice su nasađene na ploče sa šest jažica i tretirane s 2 M spojem 1 tijekom 48 sati. Nakon toga, stanice su obojane s protu-GD3, protu-CD44 i protu-CD24 protutijelima, a zatim analizirane protočnom citometrijom. Prikupljanje podataka trostruko obojenih stanica rađeno je citometrom BD Accuri C6 (BD Biosciences) i analizirano softverom FlowLogic. Rezultati: Tretman MDA-MB-231 stanica spojem 1 doveo je do smanjenja ekspresije GD3 na CD44+/CD24- CSC, kao i CD44- epitelnim stanicama. Ekspresija GD3 na hibridnim stanicama CD44+/CD24+ nije bila značajno smanjena. Zaključak: Zbog svoje sposobnosti smanjenja ekspresije GD3 u različitim subpopulacijama raka dojke, spoj 1 ima potencijal za upotrebu u liječenju trostruko-negativnog raka dojke.
Keywords
Keywords (croatian)
Languageenglish
URN:NBNurn:nbn:hr:171:067672
Study programmeTitle: Medical Studies in English
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2021-07-19 13:18:46